Skip to main content
    O

    Ocugen Inc (OCGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.77
    -0.05 (-6.62%)

    Market Cap: $280.88M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ocugen Inc (OCGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Ocugen reported revenue of $4.41M for the fiscal year ended Dec 31, 2025, up 8.8% from the year before. That year, net income was -$67.85M with a net margin of -1537.4%, operating cash flow was -$56.96M and free cash flow was -$57.15M. The quarter ended Sep 30, 2026 had revenue of $1.95M and net income of -$3.60M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $43.00K, a compound annual rate of 152.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.41M+8.8%100.0%-1425.7%-1537.4%
    Dec 2024$4.05M-32.8%100.0%-1350.4%-1333.0%
    Dec 2023$6.04M+142.6%100.0%-1085.7%-1045.0%
    Dec 2022$2.49MN/A100.0%-3580.0%-3488.9%
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$43.00KN/A100.0%-49500.0%-50748.8%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.41M$4.05M$6.04M$2.49M$0$43.00K$0$0$0$0
    Gross profit$4.41M$4.05M$6.04M$2.49M$0$43.00K$0$0$0$0
    Research and development$39.75M$32.13M$39.57M$56.16M$35.11M$13.35M$8.09M$10.32M$15.57M$21.58M
    Operating income-$62.92M-$54.76M-$65.53M-$89.07M-$58.03M-$21.29M-$14.16M-$16.14M-$24.95M-$30.31M
    Net income-$67.85M-$54.05M-$63.08M-$86.80M-$58.37M-$21.82M-$20.24M-$18.22M-$26.41M-$16.21M
    EBITDA-$59.83M-$52.63M-$65.01M-$88.69MN/A-$21.00MN/A-$14.44MN/A-$14.47M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.95M$1.49M$1.53M-$193.00K$1.75M$1.37M$1.48M$764.00K$1.14M$1.14M$1.01M$1.41M
    Gross profit$1.95M$1.49M$1.53M-$193.00K$1.75M$1.37M$1.48M$764.00K$1.14M$1.14M$1.01M$1.41M
    Operating income-$17.75M-$16.44M-$17.84M-$17.00M-$17.63M-$13.79M-$14.50M-$13.84M-$13.25M-$15.45M-$12.22M-$11.53M
    Net income-$3.60M-$24.88M-$19.18M-$17.71M-$20.05M-$14.74M-$15.35M-$13.88M-$12.97M-$15.28M-$11.92M-$10.97M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $28.79M exceeded cash and equivalents by $10.22M. Shareholder equity was negative, at -$12.17M, as total liabilities of $55.68M exceeded total assets of $43.52M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$43.52M$82.44M$64.55M$108.63M$105.76M$27.38M$16.81M$2.45M$11.04M$36.08M
    Current assets$24.34M$61.68M$42.97M$98.49M$102.65M$25.88M$15.77M$1.94M$8.18M$32.08M
    Cash and equivalents$18.57M$58.51M$39.46M$77.56M$94.96M$24.04M$7.44M$1.63M$7.08M$31.91M
    Total liabilities$55.68M$52.81M$23.98M$34.65M$9.94M$5.83M$5.79M$15.16M$22.30M$22.51M
    Short-term debt$1.25M$1.33M$0$498.00K$363.00K$234.00K$0$7.48M$178.00K$583.00K
    Long-term debt$27.54M$27.34M$2.80M$2.29M$1.71M$1.82M$1.07M$1.02M$961.65K$178.00K
    Shareholder equity-$12.17M$29.63M$40.56M$73.98M$95.82M$21.55M$11.02M-$12.71M-$11.27M$13.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$108.06M$124.21M$56.91M$44.29M$57.60M$53.59M$64.46M$82.44M$61.94M$40.54M$51.79M$64.55M
    Total liabilities$125.74M$140.76M$51.10M$56.45M$54.06M$50.54M$48.55M$52.81M$21.31M$23.61M$21.53M$23.98M
    Cash and equivalents$24.63M$100.05M$31.86M$18.57M$32.56M$27.01M$37.80M$58.51M$38.70M$15.70M$26.38M$39.46M
    Shareholder equity-$17.68M-$16.56M$5.80M-$12.17M$3.53M$3.05M$15.91M$29.63M$40.63M$16.93M$30.26M$40.56M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$56.96M-$42.14M-$62.05M-$60.08M-$47.94M-$14.71M-$16.89M-$11.63M-$23.02M-$25.74M
    Capital expenditures$185.00K$3.38M$10.48M$4.46M$939.00K$307.00K$30.00K$77.41K$276.00K$320.00K
    Free cash flow-$57.15M-$45.53M-$72.53M-$64.54M-$48.88M-$15.02M-$16.92M-$11.71M-$23.30M-$26.06M
    Dividends paidN/AN/AN/AN/AN/AN/A$6.80MN/AN/AN/A
    Share repurchases$1.53M$2.89M$355.00K$549.00K$8.53M$1.48M$48.00K$0N/AN/A
    Investing cash flow-$311.00K-$3.38M$3.08M-$16.97M-$1.82M-$307.00K-$2.36M-$77.41K-$1.23M-$320.00K
    Financing cash flow$17.33M$64.86M$20.88M$59.48M$120.68M$31.61M$25.07M$7.18M-$577.00K$27.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.74M-$12.20M-$21.79M-$13.96M-$12.92M-$10.73M-$19.36M-$10.36M-$11.27M-$9.91M-$10.60M-$11.30M
    Capital expenditures$149.00K$21.00K$6.00K$35.00K$91.00K$43.00K$16.00K$13.00K$507.00K$513.00K$2.35M$2.72M
    Free cash flow-$15.89M-$12.22M-$21.80M-$14.00M-$13.01M-$10.77M-$19.37M-$10.38M-$11.78M-$10.42M-$12.95M-$14.02M
    Last 12 quarters

    Frequently Asked Questions About OCGN

    What is Ocugen's annual revenue?

    Ocugen reported revenue of $4.41M for the fiscal year ended Dec 31, 2025.

    How fast is Ocugen's revenue growing?

    Revenue was up 8.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 21.0%.

    Is Ocugen profitable?

    No. Ocugen reported net income of -$67.85M for the fiscal year ended Dec 31, 2025, with a net margin of -1537.4%.

    How much free cash flow does OCGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$56.96M minus capital expenditures of $185.00K produced free cash flow of -$57.15M.

    How much debt does Ocugen have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $27.54M, short-term debt of $1.25M and cash and equivalents of $18.57M.